• 1
    Brooks HL, Mandava N, Pizzi WF, Shah S. Inflammatory breast carcinoma: a community hospital experience. J Am Coll Surg 1998;186: 6229.
  • 2
    Chambler AF, Drew PJ, Hill AD, Darzi A, Monson JR. Inflammatory breast carcinoma. Surgical Oncol 1995;4: 24554.
  • 3
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991;324: 18.
  • 4
    Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103: 12316.
  • 5
    Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5: 4348.
  • 6
    Takakura N, Watanabe T, Suenobu S, Yamada Y, Noda T, Ito Y, Satake M, Suda T. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000;102: 199209.
  • 7
    Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ, Quyyumi AA, Finkel T. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999;59: 58757.
  • 8
    Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000;105: 152736.
  • 9
    Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5: 135964.
  • 10
    Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. 1999. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284: 19948.
  • 11
    Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis and mortality rate. Proc Natl Acad Sci USA 1998;95: 8795800.
  • 12
    Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90: 107059.
  • 13
    Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1 and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226: 3248.
  • 14
    Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, Kondo Y, Gorrin-Rivas MJ, Furumoto K, Kaneda Y, Imamura M. 2000. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 2000;7: 102733.
  • 15
    Bett AJ, Haddara W, Prevec L, Graham FL. A highly efficient and flexible system for construction of human adenovirus type 5 vectors with insertions or deletions in early region 1 and early region 3. Proc Natl Acad Sci USA 1994;91: 88026.
  • 16
    Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Dewhirst NW, George SE. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998;95: 882934.
  • 17
    Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87: 117180.
  • 18
    Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, Martiny-Baron G. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999;59: 318591.
  • 19
    Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, Konishi F, Terada M, et al. Absence of endothelial cells, central necrosis and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61: 44551.
  • 20
    Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97: 365861.
  • 21
    Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77: 162752.
  • 22
    Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. 2001. Vascular endothelial growth factor is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98: 190413.